Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14007MR)

This product GTTS-WQ14007MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14007MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7928MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ14811MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ9192MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ9654MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ10561MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ5525MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ4004MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ8171MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW